Autor(es): Melo, Ana Teresa ; Campanilho-Marques, Raquel ; Fonseca, João Eurico
Data: 2020
Identificador Persistente: http://hdl.handle.net/10451/53078
Origem: Repositório da Universidade de Lisboa
Assunto(s): Immune-mediated inflammatory diseases; Golimumab; Tnf inhibitors
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine and its overexpression has been implicated in the pathophysiology of several chronic immune-mediated inflammatory diseases. Biological therapies, like TNF inhibitors, have been revolutionizing the course of these disorders. Golimumab is a transgenic anti-TNF monoclonal antibody that acts primarily by targeting and neutralizing TNF, thus preventing inflammation. It is approved for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Nonradiographic axial Spondyloarthritis, Juvenile Idiopathic Arthritis, and Ulcerative Colitis. Clinical trials are also being conducted in other conditions. This review charts the clinical development of golimumab and outlines the data that support its potential use across several Immune-mediated inflammatory diseases.
